Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AGEX THERAPEUTICS, INC.

(AGE)
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
0.7(c) 0.6999(c) 0.661(c) 0.64195(c) 0.62(c) Last
172 327 116 559 141 434 78 100 93 124 Volume
-2.80% -0.01% -5.56% -2.88% -3.42% Change
More quotes
Estimated financial data (e) (USD)
Sales 2019 1,73 M - -
Net income 2019 -12,2 M - -
Net cash position 2019 0,40 M - -
P/E ratio 2019 -5,58x
Yield 2019 -
Sales 2020 1,87 M - -
Net income 2020 -10,9 M - -
Net Debt 2020 5,77 M - -
P/E ratio 2020 -5,27x
Yield 2020 -
Capitalization 23,5 M 23,5 M -
EV / Sales 2019 39,4x
EV / Sales 2020 33,8x
Nbr of Employees 9
Free-Float 56,5%
More Financials
Company
AgeX Therapeutics Inc. is a biotechnology company. The Company is focused on the development and commercialization of therapeutics targeting human aging and degenerative diseases. Its product pipeline includes two cell-based and two induced Tissue Regeneration (iTR) based product candidates in development. The Company’s AGEX-BAT1 is its cell therapy product candidate that is being developed for the treatment of... 
More about the company
All news about AGEX THERAPEUTICS, INC.
11/30AgeX Therapeutics' Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosi..
BU
11/24AgeX Therapeutics, Inc. Approves to Elect Joanne Hackett as Director
CI
11/23AGEX THERAPEUTICS : RECEIVES STOCK EXCHANGE DEFICIENCY LETTER - Form 8-K
PU
11/23AGEX THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Ru..
AQ
11/23AgeX Therapeutics Receives Stock Exchange Deficiency Letter
BU
11/12AGEX THERAPEUTICS : Reports Third Quarter 2021 Financial Results - Form 8-K
PU
11/12AGEX THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
11/12Earnings Flash (AGE) AGEX THERAPEUTICS Reports Q3 Revenue $24,000
MT
11/12AgeX Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months ..
CI
11/12AgeX Therapeutics Reports Third Quarter 2021 Financial Results
BU
11/09AGEX THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements..
AQ
11/09AgeX Therapeutics, Inc. Enters into Amendment No. 2 to Loan Facility Agreement
CI
10/26AGEX THERAPEUTICS, INC. : Creation of a Direct Financial Obligation or an Obligation under..
AQ
09/03AGEX THERAPEUTICS, INC. : Creation of a Direct Financial Obligation or an Obligation under..
AQ
08/13AGEX THERAPEUTICS : Reports Flat Q2 Net Loss; Reiterates Going-Concern Warning
MT
More news
News in other languages on AGEX THERAPEUTICS, INC.
11/12Earnings Flash (AGE) AGEX THERAPEUTICS annonce un revenu de 24 000 $ pour le troisième ..
08/16MÄRKTE USA/Uneinheitlich - Dow und S&P-500 mit neuen Rekordhochs
08/16MÄRKTE USA/Schwache Daten aus China und USA animieren zu Gewinnmitnahmen
08/16MÄRKTE USA/Schwache Daten aus China und USA drücken
08/16MÄRKTE USA/Wall Street mit schwachen China-Daten leichter erwartet
More news
Chart AGEX THERAPEUTICS, INC.
Duration : Period :
AgeX Therapeutics, Inc. Technical Analysis Chart | AGE | US00848H1086 | MarketScreener
Income Statement Evolution
Managers and Directors
Michael D. West President, Chief Executive Officer & Director
Andrea E. Park Chief Financial Officer
Gregory H. Bailey Chairman
Hal Sternberg Vice President-Research
Ivan Labat Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
AGEX THERAPEUTICS, INC.-57.77%24
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819